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Background: Dengue is a major public health problem worldwide. Assessment of 
adaptive immunity is important to understanding immunopathology and to define 
correlates of protection against dengue virus (DENV). To enable global assessment of 
CD4+ T cell responses, we mapped HLA-DRB1-restricted DENV-specific CD4+ T cell 
epitopes in individuals previously exposed to DENV in the general population of the 
dengue-endemic region of Managua, Nicaragua.
Methods: HLA class II epitopes in the population of Managua were identified by an 
in vitro IFNγ ELISPOT assay. CD4+ T cells purified by magnetic bead negative selection 
were stimulated with HLA-matched epitope pools in the presence of autologous anti-
gen-presenting cells, followed by pool deconvolution to identify specific epitopes. The 
epitopes identified in this study were combined with those previously identified in the 
DENV endemic region of Sri Lanka, to generate a “megapool” (MP) consisting of 180 
peptides specifically designed to achieve balanced HLA and DENV serotype coverage. 
The DENV CD4MP180 was validated by intracellular cytokine staining assays.
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results: We detected responses directed against a total of 431 epitopes, representing 
all 4 DENV serotypes, restricted by 15 different HLA-DRB1 alleles. The responses were 
associated with a similar pattern of protein immunodominance, overall higher magnitude 
of responses, as compared to what was observed previously in the Sri Lanka region. 
Based on these epitope mapping studies, we designed a DENV CD4 MP180 with higher 
and more consistent coverage, which allowed the detection of CD4+ T  cell DENV 
responses ex vivo in various cohorts of DENV exposed donors worldwide, including 
donors from Nicaragua, Brazil, Singapore, Sri Lanka, and U.S. domestic flavivirus-naïve 
subjects immunized with Tetravalent Dengue Live-Attenuated Vaccine (TV005). This 
broad reactivity reflects that the 21 HLA-DRB1 alleles analyzed in this and previous 
studies account for more than 80% of alleles present with a phenotypic frequency ≥5% 
worldwide, corresponding to 92% phenotypic coverage of the general population (i.e., 
92% of individuals express at least one of these alleles).
conclusion: The DENV CD4 MP180 can be utilized to measure ex vivo responses to 
DENV irrespective of geographical location.
Keywords: dengue virus, cD4+ T cells, hla, epitope, adaptive immunity
inTrODUcTiOn
Infection with dengue virus (DENV) is an ever-increasing public 
health issue of global concern. DENV is endemic in more than 
120 countries, with more than 40% of the world population at 
risk of DENV transmission (1, 2). Overall, it has been estimated 
that there are up to 100 million cases of dengue infection per year 
(3). Infections with any of the four different DENV serotypes can 
either be asymptomatic, as it is in more than 75% of the cases, or 
lead to clinical manifestations ranging from mild febrile illness 
(dengue fever, DF) to severe disease (dengue hemorrhagic fever, 
DHF) and shock syndrome with plasma leakage (dengue shock 
syndrome) (2, 4).
The role of T cells in severe dengue disease has been a topic 
of spirited debate and remains controversial. A role for T cells in 
the immunopathogenesis of the virus has been proposed based 
on the higher TNFα vs IFNγ production seen in DHF, and the 
suboptimal degranulation and cytokine production with heter-
ologous peptides stimulation (5–7). Conversely, several studies 
have proposed a protective role for DENV-specific CD4+ and 
CD8+ T  cells with increased frequency in subclinical infection 
relative to severe disease, effective antiviral activity of CD8+ 
T  cells during secondary DENV infection and HLA-restricted 
protective responses associated with specific phenotypes and 
polyfunctionality (8–12). The general consensus is that in addi-
tion to antibodies, CD8+ and CD4+ T cell responses should be 
taken into consideration in accounting for a complete DENV-
specific adaptive immunity.
Several issues need to be addressed to enable the global 
assessment of T  cell responses. First, accurate assessment of 
responses requires the identification of a sufficient number of 
T cell epitopes. We and others (12–16) have studied responses 
observed in the general population in endemic areas to define 
the epitope repertoire associated with at least partial natural 
immunity. Second, geographic variations in HLA frequencies 
underscore the necessity of defining sets of epitopes that can elicit 
responses restricted by the most representative and common 
HLA alleles worldwide. Thus, it is important that epitope identi-
fication studies are conducted in different geographical locations, 
to enable identification of epitopes restricted by a diverse set of 
HLA molecules.
We previously determined the repertoire of DENV-specific 
CD8+ T cell responses in the endemic region of Colombo (Sri 
Lanka) and reported that different HLA alleles are associ-
ated with differential magnitudes of response (13). When the 
repertoire of CD8+ T cell responses was assessed in a different 
cohort of donors derived from the endemic region of Managua, 
Nicaragua, we observed a very similar HLA-associated hierarchy 
of responses (11).
Similarly, when the repertoire of DENV-specific CD4+ T cell 
responses in the Colombo region of Sri Lanka was determined, 
different HLA-DRB1 alleles were associated with different mag-
nitudes of responses (12). In this study, we examined the DENV-
specific CD4+ T cell responses in the Managua region and asked 
whether HLA-specific CD4+ T cell responses in Nicaragua and Sri 
Lanka were also similarly correlated.
In addition to a repertoire of epitopes spanning the most com-
mon HLA types, it is important to be able to assess responses 
directly ex vivo, so that the phenotypes are not altered. It is also 
critical to evaluate T cell responses in small sample volumes, as 
often only small volumes are available in large scale vaccine trials 
or study of severe DENV disease, especially in pediatric patients. 
To meet these challenges, we developed the megapool (MP) 
approach, which is based on a large numbers of peptides pooled 
and formulated via sequential lyophilization (17). DENV MPs 
for both CD8+ and CD4+ T  cell epitopes have been previously 
reported (12, 14). The study of T cell responses in different set-
tings and geographical locations is important in the definition 
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of MPs that are truly global. Accordingly, we leveraged the 
combined information derived from our previous studies and 
this investigation of the CD4+ T cell repertoire in the Managua 
region to specifically design a comprehensive and widely applica-
ble DENV CD4 MP that can detect T cell immune responses ex 
vivo independently of the HLA class II haplotypes represented in 
a given population.
MaTerials anD MeThODs
human Blood samples
Blood bank samples from endemic areas were obtained from 
healthy adult blood donors from the Nicaraguan National Blood 
Center, Managua and from National Blood Center, Ministry of 
Health, Colombo, Sri Lanka, in an anonymous fashion, as previ-
ously described (11–14). We also studied a cohort of volunteers 
from Burlington, VT, Baltimore, MD, and Washington, DC, who 
were flavivirus naïve at the time of vaccination with a live-atten-
uated tetravalent DENV vaccine formulation (DLAV, TV005), 
as previously described (18, 19). Negative controls were healthy 
volunteers from San Diego, CA, who were tested and found to be 
seronegative for all DENV serotypes and yellow fever virus, and 
therefore defined in this study as “flavivirus naïve.” To verify the 
reactivity of the DENV epitopes, additional independent cohorts 
of DENV cases were selected in several endemic regions from 
Brazil, Singapore, and India. Peripheral blood mononuclear cells 
(PBMCs) were isolated by Ficoll density gradient centrifugation 
and frozen in fetal bovine serum supplemented with 10% DMSO 
(13, 14). Seropositivity to DENV was determined by testing 
for total anti-DENV antibodies by inhibition ELISA or antigen 
capture ELISA and modified microFRNT assay for neutraliza-
tion titer (conducted at the National Virology Laboratory of 
the Nicaraguan Ministry of Health and the University of North 
Carolina, Chapel Hill, respectively), as previously described 
(20–22). All samples were collected and used following guide-
lines from the Institutional Review Boards (IRBs) of the La Jolla 
Institute for Allergy and Immunology (LIAI), the University of 
California, Berkeley, the Nicaraguan Ministry of Health, and the 
Medical Faculty, University of Colombo (serving as the National 
Institutes of Health-approved IRB for Genetech Research 
Institute) and clinical trials registered at ClinicalTrials.gov under 
registration numbers NCT01506570 and NCT01436422.
Brazil
Longitudinal samples were collected during the 2014 and 2015 
outbreaks at the Hospital das Clinicas Universidade de São Paulo 
with acute and convalescent dengue specimens stored in the 
sample repository. The infecting DENV serotype was determined 
in all patients by RT-PCR. Samples obtained at least 1  month 
after the onset of acute dengue symptoms were made available 
for this study. All participants signed the IRB-approved informed 
consent document (IRB document 0652/09, CAPPesq, Hospital 
das Clínicas, Universidade de São Paulo).
Singapore
A cohort of DF cases was established at Tan Tock Seng Hospital 
enrolling patients with suspected DENV. DENV diagnosis was 
confirmed by the detection of DENV RNA by reverse transcrip-
tion polymerase chain reaction, or of NS1 antigen by enzyme-
linked immunosorbent assay (Bio-Rad), as previously described 
(9). The 16 samples used in this study were collected in the late 
convalescent phase 60–160 days after fever onset and all partici-
pants gave informed consent. Collection of PBMCs was approved 
by the Singapore National Healthcare Group ethical review board 
(DSRB 2008/00293).
India
Healthy adults were recruited into the study after advertisement 
by the Indian Institute of Science (IISc) and the National Institute 
of Mental Health and Neurosciences (NIMHANS), both in 
Bengaluru, Karnataka State, India, as part of a study on Japanese 
encephalitis (JE) and JE vaccine. The study was conducted 
according to the principles of the Declaration of Helsinki. All 
participants gave written informed consent and the protocol was 
approved by the IISc Institutional Human Ethics Committee 
(ref 5/2011). Previous exposure to DENV was determined by 
neutralization titers against all four serotypes, as previously 
described (23).
hla Typing and Phenotype Frequency 
calculations
Donors were HLA typed by an ASHI-accredited laboratory at 
Murdoch University (Western Australia). HLA typing was performed 
for Class I (HLA A; B; C) and Class II (DQA1; DQB1, DRB1 3, 4, 5; 
DPB1), as previously described (12, 19, 24). Average phenotype fre-
quencies for individual DRB1 alleles in the worldwide population are 
based on data available at DbMHC [NCBI (25)] and allelefrequencies.
net (26), and were calculated as previously described (27–29). Briefly, 
for each HLA allele, an average gene frequency (gf) across Europe, 
North Africa, North-East Asia, South Pacific (Australia and Oceania), 
Hispanic North and South America, American Indian, South-East 
Asia, South-West Asia, and Sub-Saharan Africa populations was cal-
culated, and an average phenotypic frequency (pf) was then derived 
utilizing the binomial distribution formula: pf = 1 − (1 − Σgf)2.
Mhc class ii-Binding Predictions  
and Peptide selection
A set of DENV peptides predicted to bind various HLA-DRB1 
allelic variants (DRB1*01:01, 01:02, 03:01, 04:03, 04:07, 07:01, 
08:02, 09:01, 11:01, 11:04, 13:01, 14:02, 14:06, 15:01) was chosen 
according to the criteria described in the Section “Results” to 
assess DENV-specific HLA-restricted CD4+ T  cell responses. 
Fifteen-mer peptides from all four serotypes were selected based 
on their predicted binding affinity to the selected MHC class II 
molecules (12, 30, 31). This resulted in the synthesis of more than 
1,900 predicted HLA-DRB1-binding peptides (Mimotopes, VIC, 
Australia). Of a total of 1,931 peptides tested, 398 (21%) were 
predicted to bind two or more DRB1 alleles, and only 138 (7%) 
were predicted to bind to three or more. For screening studies, the 
class II peptides were combined into pools of approximately 20 
individual peptides, according to their predicted HLA restriction, 
resulting in approximately 7 pools per HLA allele. Table S1 in 
Supplementary Material lists the number of peptides synthetized 
FigUre 1 | Phenotypic frequency of different HLA-DRB1 allelic variants in Nicaragua, Sri Lanka, and worldwide populations. The HLA-DRB1 phenotypic frequency 
from 334 Nicaraguan donors (gray bars) were compared to frequencies in Sri Lanka donors [(12); white bars] and worldwide (calculated as described in Section 
“Materials and Methods”; black bars). Red arrows indicate DRB1 alleles studied for epitope identification in this study only (not previously studied in Sri Lanka). 
Green arrows indicate DRB1 alleles not considered for epitope identification in this study, but previously addressed by the Sri Lankan studies. Blue arrows indicate 
DRB1 alleles studied for epitope identification in this study, and also previously addressed in the Sri Lankan studies.
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for each allele and serotype. For MP generation, each individual 
peptide was resuspended in 40 mg/ml DMSO. All resuspended 
peptides were then pooled and re-lyophilized. The resulting 
lyocake was resuspended in DMSO corresponding to a concen-
tration of 1 mg/ml of each individual peptide and then diluted 1:4 
in distilled water. Similarly, a set of 122 previously defined CMV- 
and EBV-specific peptides was resuspended as a MP (1 mg/ml) 
and used as a control pool in the intracellular cytokine staining 
(ICS) experiments (17).
In Vitro expansion of DenV-specific T cells
CD4+ T  cells isolated from thawed PBMCs by magnetic bead 
negative selection and autologous antigen-presenting cells (APCs) 
were cultured in RPMI 1640 (Omega Scientific) supplemented 
with 5% human serum (Cellgro) at a 2:1 ratio and a density of 
2 × 106 and 1 × 106 cells/ml, respectively, in 24-well plates (BD 
Biosciences). Cells were stimulated with DENV-specific peptide 
pools (averaging 20 peptides per pool) and incubated at 37°C 
in 5% CO2. IL-2 (10  U/ml; eBioscience) was added 4, 7, and 
11 days after initial antigenic stimulation. Cells were harvested 
and screened for individual DENV-specific peptide reactivity on 
day 14.
iFnγ elisPOT assay
Peripheral blood mononuclear cells (5 × 104) were incubated in 
triplicates with 0.1 ml complete RPMI 1640 in the presence of 
HLA-matched peptide pools and individual peptides (2 µg/ml) 
after 14 days of in vitro expansion. After 20 h of incubation at 
37°C, cells were incubated with biotinylated IFNγ mAb (mAb 
7-B6-1 Mabtech, Stockholm, Sweden) for 2 h and developed as 
previously described (10, 13).
Flow cytometry
For ICS, PBMCs were cultured in the presence DENV CD4 MPs 
and CMV/EBV MP (1–2 µg/ml) for 2 h prior to the addition of 
GolgiPlug containing brefeldin A (BD Biosciences, San Diego, 
CA, USA) and further incubation for 4 h. At the end of the stimu-
lation, cells were stained for surface markers, then permeabilized, 
and finally stained for intracellular markers, and then analyzed 
as previously described (13). Gating strategy is summarized in 
Figure S1 in Supplementary Material.
resUlTs
analysis of hla Frequencies in nicaragua 
and selection of Target alleles
Previous studies in the DENV endemic region of Colombo, 
Sri Lanka, analyzed a total of 16 HLA-DRB1 alleles present at 
frequencies of ≥5% in that population (12). Here, we expanded 
our analysis of HLA-DRB1-restricted responses to the Managua 
region in Nicaragua, which is also endemic for DENV infections. 
As a first step, we performed HLA typing on PBMCs from 334 
healthy blood bank donors. The frequency of different HLA-DRB1 
alleles was analyzed to identify alleles frequent in Nicaragua and 
not covered by the previous Sri Lanka study.
Figure 1 shows the phenotypic frequency of alleles found at a 
frequency of 5% or greater in the Nicaraguan cohort (Figure 1, 
gray bars) and in the previously assessed Sri Lanka cohort 
(Figure 1, white bars) (12). The average allele frequency in the 
global worldwide population, calculated as described in the 
Section “Materials and Methods,” is also shown for comparison 
(Figure  1, black bars). To expand coverage of the Nicaraguan 
cohort, five HLA-DRB1 alleles that were not previously studied, 
TaBle 1 | CD4+ T cell dengue virus (DENV) immunoreactivity in peripheral blood mononuclear cells from the Nicaraguan cohort studied.
hla DrB1* allele Total response 
magnitude/donor
average # of  
epitopes/donor
DenV proteins
c prM e ns1 ns2a ns2B ns3 ns4a ns4B ns5
0101 11,300 6.6 7,191 172 0 292 324 556 2,343 0 422 0
0102 10,998 9.9 132 0 455 0 2,332 167 5,954 417 1,045 495
0301 8,557 9.5 0 0 162 3,054 495 751 1,500 0 1,941 654
0403 8,575 7.8 1,505 0 3,176 68 462 0 1,466 157 0 1,741
0407 15,958 13.5 6,441 0 2,033 636 514 0 5,856 0 64 414
0701 11,308 11.5 1,897 666 1,211 742 1,854 224 2,043 0 1,406 1,266
0802 5,758 9.8 1,124 126 275 0 0 619 1,020 62 0 2,532
0901 9,964 7.2 2,663 264 93 676 321 0 997 0 338 4,612
1101 25,412 18.7 9,658 1,236 1,774 0 2,836 90 3,747 915 251 4,905
1104 5,708 5.4 0 0 597 749 1,718 0 505 100 0 2,039
1301 17,888 13.7 3,565 0 123 0 3,649 0 6,380 560 916 2,694
1402 20,681 17.1 12,914 0 3,422 0 216 0 2,648 0 137 1,345
1406 24,365 19.7 8,162 0 2,658 936 207 0 8,159 0 288 3,955
1501 16,227 11.8 1,755 951 3,165 0 439 0 5,755 2,335 1,107 719
Average 13,764 11.6 60,178 3,805 19,900 7,439 15,367 2,407 48,374 4,546 8,485 29,385
SD 6,451 4.5 30% 2% 10% 4% 8% 1% 24% 2% 4% 15%
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but present at frequency ≥5% in Nicaragua (Figure 1, red arrows), 
were targeted for the epitope identification studies described 
below.
To examine potential differences or similarities in HLA-
DRB1-associated responses in Nicaragua and Sri Lanka, we 
selected nine HLA-DRB1 alleles previously studied in Sri Lanka 
which were also present at a frequency ≥5% in Nicaragua (blue 
arrows in Figure 1). An additional seven HLA-DRB1 alleles for 
which the epitope repertoire was previously studied in Sri Lanka 
(green arrows in Figure 1) were not further analyzed in this study. 
Overall, the 21 HLA-DRB1 alleles targeted for epitope identifica-
tion studies by this and previous Sri Lankan study (marked by the 
colored arrows in Figure 1) cover 81.7% of alleles with phenotype 
frequency ≥5% worldwide. Combined, these alleles afford for 
92% phenotypic coverage worldwide (i.e., 92% of individuals 
express at least one of these alleles).
Overall cD4 reactivity in the nicaragua 
cohort for the hla-DrB1 alleles studied
Previous experiments analyzed CD4+ T cell responses restricted 
by various HLA-DRB1 alleles (12) in a cohort of Sri Lankan 
donors. Potential epitopes from each of the four DENV serotypes 
predicted to bind at least 1 of 15 HLA-DRB1 alleles were selected, 
as previously described (12). An overall summary of the number 
of predicted binders for each DENV serotype and HLA allele is 
presented in Table S1 in Supplementary Material. For each HLA-
DRB1 allelic variant considered, approximately 130 predicted 
peptides were tested in HLA-DRB1 matched donors, also as 
previously described (10).
CD4+ T cells purified through negative selection using mag-
netic beads were cultured with autologous APCs and stimulated 
with HLA-matched DENV-specific pools. On day 14, cells were 
harvested and screened for reactivity against individual DENV-
specific peptides in an IFNγ ELISPOT assay. A total of 4–10 donors 
for each of the HLA-DRB1 allelic variants were tested. A complete 
listing of all peptides tested, including response frequency and 
HLA restriction has been submitted to the Immune Epitope 
Database (IEDB)1,2 and the Immport database3 (Submission 
ID: SDY1109). The overall reactivity as a function of the differ-
ent HLA alleles and different proteins is shown in Table 1. The 
average magnitude of responses for each allele (total magnitude 
of responses detected for that allele corrected for the number of 
donors tested) was 13,764 ± 6,451 (IFNγ SFC/106 PBMC) and the 
average number of epitopes/donor recognized in the context of 
each allele was 11 ± 4 epitopes/donor.
similar Patterns of Protein 
immunodominance and higher Magnitude 
of DenV-specific responses in the 
nicaraguan cohort
Next, we considered the pattern of epitope immunoreactivity in 
the Nicaraguan cohort as a function of location within the DENV 
genome, and in comparison to the pattern previously observed 
in the Sri Lankan cohort (12). Pie charts in Figure 2 show data 
from the Nicaragua (Figure  2A) and Sri Lankan (Figure  2B) 
cohorts. The pattern of immunodominance in the two cohorts 
is remarkably similar, with the C, NS5, and NS3 antigens being 
most dominant in both, and accounting for 30 vs 31%, 24 vs 21%, 
and 15 vs 13% of the total response in the Nicaraguan and Sri 
Lankan cohorts, respectively.
We further compared the magnitude of CD4+ T cell responses 
in the Nicaraguan cohort to that previously observed in Sri 
Lankan donors (Table  2). When the 9 alleles tested in both 
cohorts are considered, the average magnitude of Nicaraguan 
responses was 12,776 ± 6,069 (IFNγ SFC/106 PBMC), while in 
the Sri Lankan study the average magnitude was 6,800 ± 4,288 
(IFNγ SFC/106 PBMC) (Table 2). The response observed in the 
1 http://www.iedb.org.
2 http://www.iedb.org/subID/1000719.
3 http://www.immport.org.
TaBle 2 | Comparison of CD4+ T cells dengue virus immunoreactivity between 
Nicaragua and Sri Lanka.
nicaragua sri lanka
Total 
magnitude
average 
epitopes per 
donor
Total 
magnitude
average 
epitopes per 
donor
DRB1*0101 11,300 6.6 5,447 6.80
DRB1*0301 8,557 9.5 2,064 3.1
DRB1*0403 8,575 7.8 3,668 4.6
DRB1*0701 11,308 11.5 11,350 9.7
DRB1*0802 5,758 9.8 3,761 2.9
DRB1*0901 9,964 7.2 10,039 10.6
DRB1*1101 25,412 18.7 1,659 2.2
DRB1*1301 17,888 13.7 11,732 10.4
DRB1*1501 16,227 11.8 11,476 7.8
Average 12,776 10.7 6,800 6.5
SD 6,069 3.8 4,288 3.4
Data from the Sri Lanka donors were published previously (12) and are shown here for 
reference purpose only.
FigUre 2 | Patterns of protein immunodominance of CD4+ T cells responses in Nicaragua and Sri Lanka. Pie charts indicate the percentage of total magnitude  
of responses per protein observed in 104 Nicaragua (a) and 154 Sri Lanka (B) donors tested using identical methodology. Data from the Sri Lanka donors were 
published previously (12) and are shown here for reference purposes only.
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Nicaraguan cohort was almost twofold higher than in the Sri 
Lankan cohort (p = 0.0315 in a two-tailed Mann–Whitney test). 
A similar trend was observed when comparing the number of 
epitopes recognized for each allele in the two cohorts (10 ± 4 vs 
6 ± 3; p = ns).
Differences in Patterns of hla-linked 
immunodominance of cD4 reactivity  
in sri lanka and nicaragua cohorts
CD8+ T cell responses measured in Sri Lankan and Nicaraguan 
healthy blood donor cohorts are associated with a very similar 
HLA-associated hierarchy of responses (11). The total response 
magnitude per donor for each HLA-DRB1 alleles analyzed in 
this study was then compared to the total magnitude of the same 
HLA-DRB1 previously tested in a Sri Lankan cohort using the 
(12). No correlation of HLA-DRB1 restriction and magnitude of 
responses was apparent (Figure 3A; R2 = 0.07291, p = 0.4823). 
Removing the “outlier” HLA-DRB1*11:01 allele with higher 
total responses magnitude per donor in the Nicaraguan cohort 
compared to the Sri Lankan cohort led to a significant, albeit weak 
correlation (Figure 3A; R2 =  0.5537, p =  0.0343). Even in this 
case, the correlation is much less than that previously observed 
in CD8+ T cell responses (R2 = 0.98) (11). The mechanism for this 
poor (or lack of) correlation was further investigated in the case 
of the HLA-DRB1*11:01 “outlier.”
We specifically tested whether the higher HLA-DRB1*11:01 
CD4+ T  cell responses in the Nicaraguan cohort were due to 
recognition of the same epitopes with higher magnitude of 
responses or, alternatively, whether the greater response to HLA-
DRB1*11:01 was due to recognition of a new and/or broader 
set of epitopes. When looking at the total number of epitopes 
identified in the 2 cohorts, 52 total HLA-DRB1*11:01 epitopes 
and on average 48 (range 39–60) total epitopes restricted to the 
other 8 HLA-DRB1 alleles were identified. Therefore, in terms of 
total number of epitopes, DRB1*11:01 does not seem to recognize 
more epitopes respect to the other alleles in this study. We then 
looked and the number of epitopes recognized only in Nicaragua, 
or only in Sri Lanka or both populations. Out of 52 total HLA-
DRB1*11:01 epitopes, 38 (73.1%) were recognized uniquely by 
CD4+ T cells from Nicaragua subjects, and only 14 (27.9%) were 
recognized in both populations or only the Sri Lankan cohort 
(Figure 3B).
In conclusion, when including all alleles studied, we did not 
observe a clear HLA-DRB1 response hierarchy of CD4+ T  cell 
responses, which is in contrast to what we have previously detected 
at the level of CD8+ T cell responses (11). Our results also suggest 
that the HLA-DRB1*11:01 allele was able to recognize a broader 
array of epitopes presented only in the Nicaraguan cohort, in 
contrast to what was observed for the other alleles, where epitope-
specific responses were detected in both cohorts (11).
epitope selection for a global  
DenV cD4 MP
Pools of large numbers of epitopes, generated by sequential lyo-
philization (17), have been utilized as a tool to globally character-
ize both CD4+ and CD8+ T cell responses. These MPs have been 
validated in a number of contexts, including allergies (32), latent 
tuberculosis infection (33), tetanus/pertussis vaccination (34, 
35), and DENV immunity (12, 14). We previously constructed 
CD4 DENV MP based on epitopes recognized by CD4+ T cells 
FigUre 3 | Correlation of HLA-restricted CD4+ T cells responses in Nicaragua and Sri Lanka cohorts. (a) Correlation of total responses magnitude per donor as a 
function of restricting HLA molecule, between Nicaraguan and Sri Lankan cohorts (R2 = 0.07291, p = 0.4823; if HLA-DRB1*11.01 is removed, R2 = 0.5537, 
p = 0.0343). (B) Comparison of the number of epitopes detected in the case of the HLA-DRB1*11:01 allele and in other eight HLA-DRB1 alleles (*01:01, *03:01, 
*04:03, *07:01, *08:02, *09:01, *13:01, and *15:01) considered in the study using one-sample t test. Bars refer to total epitopes, epitopes detected only in 
Nicaragua (NIC), and epitopes detected in Sri Lanka (SL) only or both cohorts.
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from Sri Lankan subjects (12). Here, we reevaluated the DENV 
CD4 MP by studying a broader set of epitopes than previously 
examined, including epitopes restricted by additional HLA alleles 
deriving from Nicaraguan subjects.
The previously published MP (DENV CD4 MP363) was 
composed of 363 epitopes defined in the Sri Lankan cohort 
(12). Here, we took a more structured approach to derive a new 
DENV CD4 MP (Figure  4A). First, we selected the highest 
response magnitude epitopes, considering responses in both 
the Sri Lankan and Nicaraguan cohorts, but also a previously 
described cohort of individuals immunized with a Tetravalent 
Dengue Live-Attenuated Vaccine (TV005) (19), until coverage 
of at least 50% of the total response was reached for each of the 
21 HLA-DRB1 alleles identified above. If needed, additional 
epitopes were selected to ensure that each DENV serotype was 
represented by at least four epitopes for each HLA-DRB1 allele 
(some peptides are conserved in multiple serotypes, and thus 
fewer epitopes were required to meet this criteria). Additional 
epitopes were also selected to ensure that each DENV protein 
was represented by at least five epitopes. This process resulted in 
selection of a total of 209 epitopes. In instances where sequences 
overlapped by at least 13 residues, longer peptides encompassing 
both sequences were synthetized. This resulted in a final selec-
tion of 180 epitopes, which allowed coverage of 62% of the total 
responses of all cohorts combined.
The HLA coverage and magnitude of responses of the new 
optimized DENV CD4 MP180 was compared to the previous 
DENV CD4 MP363 (Figure 4B). Across the different HLA alleles, 
the DENV CD4 MP180 provided an average coverage of 62.4% 
(±13.6) of the total response, which is higher and more consist-
ent than the previous DENV CD4 MP363 (42.0 ± 35.7%). DENV 
serotype coverage and protein representation had very similar 
patterns of coverage, with both DENV CD4 MPs providing 
fairly balanced coverage across the four serotypes (Figure S2A 
in Supplementary Material) and very similar patterns of protein 
representation (Figure S2B in Supplementary Material).
The DenV cD4 MP180 affords higher and 
More consistent coverage in Different 
Donor cohorts
To assess the capacity of the DENV CD4 MP180 to detect T cell 
responses ex vivo from DENV exposed individuals, the DENV 
CD4 MPs were next tested in ICS assays utilizing PBMCs from 
Nicaraguan and Sri Lankan donor cohorts, as well as a cohort 
of donors vaccinated with TV005 (19) (Figure 5). As expected, 
the DENV CD4 MP180 performed better in the Nicaraguan 
cohort. Specifically, significant reactivity was detected in 6 out 
of 20 donors for the DENV CD4 MP363 and 11 out of 20 donors 
for the DENV CD4 MP180. The overall magnitude of response 
between the two MPs is significant by a two-tailed Wilcoxon test 
(Figure 5A). We did not expect to see a significant difference in 
reactivity in the Sri Lankan cohort, as Sri Lankan epitopes were 
contained in both DENV CD4 MPs. Indeed, in the Sri Lankan 
cohort, significant reactivity was detected in 8 out of 20 donors 
for both DENV CD4 MPs, with no significant difference in the 
magnitude of responses (Figure 5B). Similarly, TV005-induced 
responses were detected in seven out of eight donors for both 
DENV CD4 MPs, with no significant difference in response 
magnitude (Figure 5C).
Next, we were interested to compare the performance of 
both DENV CD4 MP’s in a cohort that was not originally used 
to perform epitope identification. Accordingly, both pools were 
tested in a Brazilian cohort. Interestingly, also in a cohort that 
was not used to define the epitopes the MP180 pool works signifi-
cantly better when compared to the previously defined CD4 MP, 
FigUre 4 | Characteristics of dengue virus (DENV) CD4 MP180. (a) Strategy used to select the epitopes composing the DENV CD4 MP180. (B) Comparison of HLA 
coverage in terms of magnitude of responses for epitopes belonging to the two DENV CD4 MPs.
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confirming the better performance of DENV CD4 MP180 when 
compared to DENV CD4 MP363 (Figure 5D).
Finally, we asked whether the DENV CD4 MP180 was capable 
of globally capturing DENV reactivity when multiple cohorts 
from different geographical locations were considered. We 
specifically considered locations that are endemic for DENV 
infections and that had not provided samples for our epitope 
identification studies. Accordingly, we analyzed responses 
in PBMCs derived from Brazilian, Singaporean, and Indian 
cohorts. As a negative control, we assayed healthy volunteers 
from San Diego who had been tested and found to be seronega-
tive for all DENV serotypes and yellow fever virus (“flavivirus 
naïve” controls). As a positive control, we included a previously 
described CMV/EBV MP (17) (Figure 6).
As expected, flavivirus naïve donors did not show reactivity 
to DENV CD4 MP180. Also, as expected, all the cohorts showed 
similar frequencies of reactivity, in the 45–55% range, against 
the CMV/EBV MP (Figure  6). DENV exposed cohorts were 
associated with a range of reactivity between 33 and 75% against 
DENV CD4 MP180. When frequencies and magnitude of response 
between cohorts were compared, magnitude but not frequency 
of response from Brazil was significantly higher compared to all 
other cohorts (Table S2 in Supplementary Material). Since the 
Brazilian cohort was not used to define the epitopes included in 
MP180, the most likely explanation is that these differences are 
due infection history and not MP composition. Nevertheless, the 
data should be interpreted with this caveat in mind.
DiscUssiOn
In this study, we analyzed the epitopes recognized by DENV-
specific CD4+ T  cells in the context of different HLA alleles 
FigUre 6 | Assessment of dengue virus (DENV) CD4 MP180 reactivity in diverse geographical locations. Percentage of CD4+ T cells producing IFNγ upon stimulation 
with DENV CD4 MP180 in flavivirus naïve (n = 10) (a) and DENV exposed Singaporean (n = 16) (B), Indian (n = 9) (c), and Brazilian (n = 20) (D) donor cohorts. CMV/
EBV CD4 MP stimulation was used as a control. To allow for comparison of the responses frequencies against the CMV/EBV and the dengue-specific response in 
all new cohorts the data showing response frequencies against the DENV CD4 MP180 in the Brazilian cohort from Figure 5D has been re-plotted in Figure 6D. Data 
are expressed as mean ± SEM, and the dashed lines at 0.02% represent the cutoff of positivity.
FigUre 5 | Comparison of CD4+ T cell reactivity to dengue virus (DENV) CD4 MP363 and DENV CD4 MP180. Percentage of CD4+ T cells producing IFNγ upon 
stimulation with the two DENV CD4 MPs in Nicaraguan (n = 20) (a), Sri Lankan (n = 20) (B) DLAV (n = 8) (c), and Brazilian (n = 20) (D) donor cohorts. Data are 
expressed as mean ± SEM. Statistical analyses were performed using two-tailed Wilcoxon test. *p < 0.05; **p < 0.01; ns, not significant. The dashed lines at 0.02% 
represent cutoff of positivity.
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in the general population of Nicaragua, where DENV is 
highly endemic. Comparison of the patterns of responses to 
those previously defined using identical methodology in the 
Colombo endemic area of Sri Lanka revealed a striking simi-
larity in the overall pattern of recognition at the antigenic level 
(12). Using the knowledge derived from the combined analysis 
in the two locations, we derived a MP of epitopes (DENV CD4 
MP180) and showed that it can be applied to the study of DENV 
responses in PBMC samples derived from disparate geographi-
cal locations.
Several lines of evidence indicate that T cells play an important 
role in the control of DENV infection, disease pathogenesis, and 
responses to vaccination (36, 37). This suggests that, in parallel 
with antibody response, T  cell responses should be measured 
and analyzed to achieve a complete assessment of DENV-specific 
adaptive immunity. In addition, peripheral CD4+ T cells prob-
ably contain a fraction of circulating memory follicular T helper 
cells that are relevant for B cell differentiation and the production 
of neutralizing antibodies (38, 39). Since DENV infection and 
disease is a worldwide and ever-increasing problem, a global 
approach to assess T cell responses in different human popula-
tions is required. While several studies have analyzed CD8+ T cell 
responses against DENV (11, 13, 15, 40, 41), less information is 
available on their CD4+ T cell counterparts (12, 42). In this con-
text, investigating DENV-specific HLA-restricted CD4+ T  cell 
epitopes recognized in different DENV endemic populations 
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and restricted by a broad variety of HLAs is necessary to evalu-
ate potential genetic and geographical factors affecting DENV 
reactivity.
Our strategy expands previous studies on HLA-DRB1 locus-
specific responses in the DENV endemic region of Colombo, 
Sri Lanka (12), to increase the HLA-DRB1 coverage from 16 
to 21 of the most common alleles. We estimate that together 
these alleles provide phenotypic coverage of 92% of individuals 
in the general worldwide population, thus accomplishing our 
goal of enabling global coverage of the HLA-DRB1 locus. This 
statement should be interpreted with two caveats in mind: first, 
certain alleles not particularly common on a worldwide basis 
might be common in particular populations. In these cases, 
additional epitope identification studies may be required to fill 
gaps in coverage for a specific population. Second, our strategy 
does not include the DRB3/4/5, DP, and DQ loci. We have pre-
viously shown that epitope predictions performed on the main 
DRB1 molecules should be able to cover approximately 50% 
of the total CD4+ T cell response (43). Despite this evidence, 
future studies are planned to expand the coverage of DENV 
CD4+ T cell epitopes by considering those loci. Third, we note 
that our assignment of these responses to the HLA DRB1 locus 
is based on binding predictions and correspondence with 
donor HLA type. However, it is possible, given the well-known 
crossreactivity of HLA class II, that some of the response is in 
fact due to coexpressed DP or DQ specificities. However, we 
believe that this collection of epitopes will provide wide cov-
erage based on the fact that different HLA class II molecules 
exhibit significant inter- and intra-loci repertoire overlap (28, 
29, 44, 45) and that our epitope sets were tested in various 
geographical locations. An issue of relevance for this study is 
the accuracy and reliability of epitope prediction software, the 
IEDB runs periodic benchmarking of its tools, the latest pub-
lished benchmarking for HLA class II (31) found AUC values 
in the 0.622–0.818 range for the DRB1 alleles, the HLA class 
II molecules of interest for this study. However, it is certainly 
possible that differences in predictive capacity or performance 
may influence the results and should therefore be interpreted 
with this caveat in mind.
Nicaraguan DENV-specific CD4+ T cell responses preferen-
tially targeted C, NS3, and NS5. This pattern is in agreement with 
what we previously observed in Sri Lanka (12), as well as what 
was also detected by Rivino et al. in DENV infected donors from 
Singapore (46), suggesting a similar protein source for immuno-
dominant epitopes in different endemic areas. This finding is not 
only significant for the study of DENV CD4+ T cell immunity but 
also to the design and evaluation of vaccines. Indeed, this pattern 
of immunodominance is also observed in individuals vaccinated 
with an experimental tetravalent live-attenuated vaccine formu-
lation (TV005) and the attenuated DENV2 virus (Tonga 74) used 
as a challenge strain in a DENV human challenge model (19, 24). 
Accordingly, we conclude that the patterns of immunodominance 
induced by vaccination with attenuated DENV vaccines should 
be able to mimic natural immunity regardless of geographical 
location.
The patterns of HLA-linked immunodominance previously 
observed at the level of CD8+ T cell responses (11) in the Sri Lankan 
and Nicaraguan cohorts were virtually indistinguishable. Here, at 
the level of HLA class II, we did not detect a significant correlation 
between response magnitudes between the two cohorts. A caveat 
to this is that our results were based on a limited number of HLA 
allelic variants. In pursuing this line of inquiry, we uncovered 
the unique case of the HLA-DRB1*11:01 allele, which exhibited 
much higher reactivity in the Nicaragua cohort as compared 
to the Sri Lanka cohort. Furthermore, most of the differences 
were related to recognition of a new set of epitopes recognized 
specifically in the Nicaragua cohort. The mechanism of this is 
as yet unclear. Strong T  cell responses/donor relative to other 
alleles were observed in the case of HLA-DRB1*11:01, *14:02, 
and *14:06 alleles in the Nicaragua population. HLA-DRB1*11:01 
recognized a new and broader set of epitopes that is unique to the 
cohort from Nicaragua when compared to previously identified 
epitope sets in Sri Lanka. In the case of HLA-DRB1*14:02+ and 
*14:06+ donors with similar strong responses, this comparison 
was not possible as those alleles are not present in the Sri Lanka 
populations (Figure 1).
Thus, it is possible that that the differences observed for HLA-
DRB1*11:01 between the two populations could be observed for 
other alleles with similar magnitude of T cell response/donor. It 
is also possible that these differences may relate to the potential 
contribution of other loci in linkage disequilibrium with the 
HLA-DRB1 locus, and sharing some degree of repertoire overlap. 
The future studies of DENV CD4+ T cell epitopes restricted by 
HLA-DRB3/4/5, DP, and DQ loci will address this hypothesis.
Our original goal was to identify reagents and assay strategies 
to allow assessment of DENV CD4+ T  cell responses regard-
less of geographical location in the specific context of DENV 
disease or vaccination. This first required the identification of a 
repertoire of epitopes spanning the most common HLA types. 
In addition, it was important to adopt methodologies amenable 
to direct ex vivo analysis to avoid altering T cell phenotypes and 
to sample-preserving approaches given that volume is often 
limiting in vaccine studies and pediatric cohorts. To meet these 
challenges, our group has developed the MP approach, based on 
large numbers of peptides pooled and formulated to take into 
account sequential lyophilization (17). In this study, we refined 
the previously described DENV CD4 MP363 by incorporating 
information from the Nicaraguan study and using a rational, 
optimized, epitope selection strategy targeting balanced HLA, 
DENV serotype, and protein composition coverage in the pro-
cess of epitope selection. We validated this optimized DENV 
MP by showing that it can be used to assess DENV-specific 
CD4+ T cell responses across donors independently from HLA 
type, geographical region, or infecting serotype. It is apparent 
that different cohorts vary somewhat in reactivity to the MP180 
pool. This differential reactivity might be due to insufficient 
coverage or due to the different history of DENV infection and 
burden of the disease. The DENV cohorts from Singapore and 
India (Figures 6B,C) are associated with relatively lower levels 
of secondary DENV infection (47, 48), as compared with the 
Brazilian cohort where secondary infections were more preva-
lent, reflecting a higher burden of infection (49, 50). We have 
previously shown that multiple exposures to DENV increase the 
magnitude of CD4+ T cell DENV-specific responses relative to 
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primary infection suggesting that infection history can influ-
ence magnitude of DENV-specific T cell responses (10). Most 
importantly, we showed that the assessment can be performed 
directly ex vivo using ICS assays. This has multiple advantages 
compared to other assays such as ELISPOT. Gating strategies 
allow the exclusion of CD8+ T cell responses that might respond 
to nested MHC class I epitopes within the tested 15mer peptide. 
Furthermore, it will allow parallel phenotypic assessments 
across different studies and capture of antigen-specific T cells 
for transcriptomic analysis on a large scale. Future studies will 
address the secretion of multiple cytokines and marker expres-
sion revealing potential additional dengue-specific CD4+ T cell 
responses but also specific polarizations of T  cell responses 
between the different cohorts.
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